Understanding CTLA-11A: Potential Drug Targets and Biomarkers

Target Name: CLEC11A

NCBI ID: G6320

CLEC11A

Understanding CTLA-11A: Potential Drug Targets and Biomarkers

CLEC11A, also known as C-type lectin-11A (CTLA-11A), is a type of cytotoxic T-cell adhesion molecule (CTLA-11) that is expressed in various tissues of the human body, including the skin, hair, and nails. It is a transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. CTLA-11A plays a crucial role in immune responses by regulating the interactions between T-cells and various cell types in the body.

Recent studies have suggested that CTLA-11A may have potential as a drug target or biomarker. In this article, we will explore the biology and potential clinical applications of CTLA-11A in greater detail.

Potential Druggable Targets

Several studies have identified potential druggable residues within CTLA-11A. One of the most promising targets is the N-terminus of the protein, which contains a unique amino acid sequence known as Asp-219. Asp-219 has been shown to play a critical role in the regulation of T-cell responses and has been implicated in the development of various autoimmune diseases, including rheumatoid arthritis, lupus, and melanoma.

Another potential druggable target within CTLA-11A is the V-loop region of the protein, which is known as Res-216. Res-216 is a key structural element that is involved in the regulation of T-cell receptor (TCR) interactions and has been implicated in the development of T-cell exhaustion and immune checkpoint diseases.

Biochemical and Functional Studies

Several studies have demonstrated the involvement of CTLA-11A in various biological processes, including cell signaling, migration, and apoptosis. One of the most significant findings is the role of CTLA-11A in regulating the development and function of natural killer cells (NK cells), which play a crucial role in immune surveillance and have been implicated in the development of various cancers.

Studies have shown that increased expression of CTLA-11A is associated with poor prognosis in various types of cancer, including breast, lung, and ovarian cancers. This suggests that targeting CTLA-11A may be a promising strategy for the development of new cancer therapies.

Potential Biomarkers

The potential use of CTLA-11A as a biomarker has also been investigated. Several studies have shown that increased expression of CTLA-11A is associated with various diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

One of the most promising applications of CTLA-11A as a biomarker is its potential to serve as a diagnostic marker for cancer. Several studies have shown that increased expression of CTLA-11A is associated with poor prognosis in various types of cancer, including breast, lung, and ovarian cancers. This suggests that monitoring the levels of CTLA-11A in cancer cells may be a promising strategy for the development of new cancer therapies.

Another potential use of CTLA-11A as a biomarker is its ability to serve as a target for small molecules. Several studies have shown that the N-terminus of CTLA-11A is involved in the regulation of T-cell responses and that this region can be targeted with small molecules. The potential use of small molecules as therapeutic agents for the treatment of CTLA-11A-positive diseases is an area of ongoing research.

Conclusion

In conclusion, CTLA-11A is a cytotoxic T-cell adhesion molecule that plays a crucial role in immune responses and has been implicated in various diseases, including cancer and autoimmune disorders. Its potential as a drug target or biomarker has received significant attention in recent years, and further research is needed to fully understand its role in

Protein Name: C-type Lectin Domain Containing 11A

Functions: Promotes osteogenesis by stimulating the differentiation of mesenchymal progenitors into mature osteoblasts (PubMed:27976999). Important for repair and maintenance of adult bone (By similarity)

The "CLEC11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets